TG Therapeutics Inc (TGTX)
Receivables turnover
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 221,047 | 2,785 | 6,689 | 152 | 152 |
Receivables | US$ in thousands | 51,093 | 0 | 1,389 | — | — |
Receivables turnover | 4.33 | — | 4.82 | — | — |
December 31, 2023 calculation
Receivables turnover = Revenue ÷ Receivables
= $221,047K ÷ $51,093K
= 4.33
The receivables turnover ratio for TG Therapeutics Inc has exhibited fluctuations over the past five years. The company achieved a receivables turnover of 4.33 in 2023, a decrease from the 4.82 turnover in 2021. The absence of data for 2022 and 2020 suggests potential reporting gaps or significant changes in the company's operations. Further analysis would be required to determine the reasons behind these variations and assess the effectiveness of the company in collecting payments from its customers.
Peer comparison
Dec 31, 2023
Company name
Symbol
Receivables turnover
TG Therapeutics Inc
TGTX
4.33
Abbott Laboratories
ABT
6.01
AbbVie Inc
ABBV
4.87
Alkermes Plc
ALKS
4.93
Amphastar P
AMPH
5.61
ANI Pharmaceuticals Inc
ANIP
2.80
Arcus Biosciences Inc
RCUS
29.25
Biomarin Pharmaceutical Inc
BMRN
3.75
Bristol-Myers Squibb Company
BMY
4.12
Catalent Inc
CTLT
4.76
Catalyst Pharmaceuticals Inc
CPRX
7.44